Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CTSG | P08311 | 1/20 | 0.31 |
| ▸ | CTRC | Q99895 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304607 | 0.79 | EP300 (0.34) | CYP2C19KDM4EALDH1A1 | |
| SCHEMBL28031487 | 0.77 | EP300 (0.33) | CYP2C19 | |
| SCHEMBL8494861 | 0.76 | KDM4E (0.32) | KDM4EALDH1A1 | |
| SCHEMBL8157058 | 0.74 | EP300 (0.32) | — | |
| SCHEMBL19923437 | 0.74 | — | — | |
| SCHEMBL11799977 | 0.74 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL11797421 | 0.73 | CYP1A2 (0.34) | TSHR | |
| SCHEMBL19923508 | 0.73 | — | — | |
| Urea SCHEMBL28111813 | 0.73 | EP300 (0.31) | — | |
| SCHEMBL11810727 | 0.73 | KDM4E (0.30) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | claimed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | claimed |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | disclosed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | PARG, HNMT, PARN | ATM 2253/4885TSHR 4786/4885CYP2C19 1347/4885 |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | HNMT, PARG, PAM | ATM 2378/4885TSHR 4794/4885CYP2C19 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.